Posted by Michael Wonder on 08 Feb 2018
Novartis receives FDA approval for Cosentyx label update to include moderate-to-severe scalp psoriasis
8 February 2018 - This follows a similar European label update in June 2017.
Novartis announced today that the US FDA has approved a label update for Cosentyx (secukinumab), the first interleukin-17A inhibitor approved to treat moderate-to-severe plaque psoriasis. The updated label includes Cosentyx data in moderate-to-severe scalp psoriasis - one of the difficult-to-treat forms of the disease, which affects approximately half of all psoriasis patients.
The label update is effective in the US immediately, and is based on the proven efficacy and consistent safety profile of Cosentyx from a dedicated Phase III scalp psoriasis trial.
